PARP inhibitor treatment of such homologous recombination (HR) deficient tumor cells causes synthetic lethality, as treated cells can neither remove proliferation-associated oxidative base damage by PARP-dependent base excision repair nor by the backup pathway HR at stalled DNA replication forks [6,7,8,9]. This evidence concerns the gene PARP1 and neoplasm.